Genetically proxied inhibition of HMGCR (stains) was causally associated with reduced risk of nonmelanoma skin cancer (OR 0.982, 95% CI 0.967-0.997, <i>p</i> = 0.016 by weighted median; OR 0.977, 95% CI 0.966-0.989, <i>p</i> < 0.001 by IVW) and psoriasis (OR 0.585, 95% CI 0.378-0.905, <i>p</i> = 0.016 by IVW), while PCSK9 inhibition (alirocumab) was causally associated with reduced risk of psoriasis (OR 0.560, 95% CI 0.413-0.761 by weighted median; OR 0.564, 95% CI 0.447-0.712 by IVW; <i>p</i> < 0.001) in the ieu-b-5089 dataset. The gene discussed is HMGCR; the disease is psoriasis.